Shopping Cart

Your shopping cart is currently empty

Nateglinide

Name: Nateglinide
Brand: TargetMol
SKU: T1674
Price: 35 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T1674Cas No. 105816-04-4

Alias Senaglinide, A4166

Nateglinide (Senaglinide) is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Nateglinide has been linked to rare instances of clinically apparent acute liver injury.

Nateglinide

Copy Product Info

🥰Excellent

Purity: 99.94%

Catalog No. T1674Alias Senaglinide, A4166Cas No. 105816-04-4

Pack Size	Price	USA Warehouse	Global Warehouse
25 mg	$50	In Stock	In Stock
50 mg	$89	In Stock	In Stock
100 mg	$148	In Stock	In Stock
200 mg	$215	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$35	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.94%

Color:White

Resource Download

COA

Product Introduction

Nateglinide AI Summary

Nateglinide exhibits a range of bioactivities and pharmacokinetic properties. It has notable hypoglycemic activity, reducing blood glucose levels by more than 20% in fasting mice at a dose of 1.6 mg kg^-1 and shows insulin-releasing activity in HIT-T15 cells in high glucose conditions, with activity levels ranging from 36.3% to 124.3% across different concentrations (1 µM, 10 µM, 100 µM). The EC50 for insulin-releasing activity is 7590.0 nM. Pharmacokinetically, Nateglinide demonstrates high bioavailability (F_fraction = 0.72) and good absorption (Fa = 0.9) in humans. It has moderate hepatic (CL = 1.7 mL/min/kg) and renal clearance (CL_renal = 0.1 mL/min/kg) rates, a steady-state volume of distribution (Vdss) of 0.15 L/kg, and an elimination half-life (T1/2) of 1.5 hours. Nateglinide shows inhibitory effects on several transport and enzyme activities. It inhibits OATP1B3 and OATP1B1 transport proteins significantly, with 70.33% and 99.81% inhibition respectively at 10 µM, and also shows inhibitory activity on several transport protein assays, including MRP3 (IC50 = 104000.0 nM). Additionally, Nateglinide displays antiviral activities against SARS-CoV-2, showing an inhibition index of 0.7846 in Vero E6 cells and 2.79% inhibition rate in Caco-2 cells at 10 µM. It inhibits the SARS-CoV-2 3CL-Pro protease by 7.842% at 20 µM and shows some cell viability effects. It also exhibits moderate antihyperglycemic activity in diabetic rats with significant blood glucose reductions at 30.6%, 26.4%, and 13.8% at different time intervals post-administration. Furthermore, it affects various biomarker levels related to liver and kidney functions as well as having potential antifungal and antibacterial activities against Candida albicans, Cryptococcus neoformans, and bacterial strains like E. coli, K. pneumoniae, and S. aureus MRSA. Lastly, Nateglinide's pharmacological profile includes liver toxicity, indicated by a severity class index of 3.0, and potential bioactivity in modulating drug-induced liver injury processes. It also shows significant impacts on insulin secretion, with varying IC50 values under different glucose conditions in INS-1E cells..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Nateglinide (Senaglinide) is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Nateglinide has been linked to rare instances of clinically apparent acute liver injury.
Synonyms	Senaglinide, A4166

Chemical Properties

Molecular Weight	317.42
Formula	C₁₉H₂₇NO₃
Cas No.	105816-04-4
Smiles	C(N[C@H](CC1=CC=CC=C1)C(O)=O)(=O)[C@H]2CC[C@H](C(C)C)CC2
Relative Density.	1.104 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 60 mg/mL (189.02 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.3 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.1504 mL	15.7520 mL	31.5040 mL	157.5200 mL
5 mM	0.6301 mL	3.1504 mL	6.3008 mL	31.5040 mL
10 mM	0.3150 mL	1.5752 mL	3.1504 mL	15.7520 mL
20 mM	0.1575 mL	0.7876 mL	1.5752 mL	7.8760 mL
50 mM	0.0630 mL	0.3150 mL	0.6301 mL	3.1504 mL
100 mM	0.0315 mL	0.1575 mL	0.3150 mL	1.5752 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc